OGEN Share Price | Oragenics, Inc. Stock Analysis & Recommendation

Q: How big is Oragenics, Inc.?

Market Cap: As of Jun 18, Oragenics, Inc. has a market capitalization of 3.13 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Oragenics, Inc. reported net sales of 0.00 million and a net profit of -10.34 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -0.21 million and total assets of 1.47 million.

Q: What does Oragenics, Inc. do?

Overview:Oragenics, Inc. is a healthcare company focused on developing treatments for oral mucositis and novel antibiotics against infectious diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)Market-cap: USD 3.13 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.87Return on Equity: -1,033.41%Price to Book: 3.13Contact Details:Address: 4902 Eisenhower Blvd Ste 125, TAMPA FL: 33634-6342Tel: 1 813 2867900Fax: 1 813 2867904Website: https://www.oragenics.com/

Q: Is Oragenics, Inc. overvalued or undervalued?

As of 12 August 2016, the valuation grade for Oragenics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued given its negative financial metrics, including a P/E ratio that is not applicable due to losses, a Price to Book Value of 3.06, and an EV to EBITDA of -0.22. The return on equity (ROE) is alarmingly low at -1033.41%, reflecting severe operational challenges.In comparison to its peers, Oragenics, Inc. shows a less favorable position; for instance, Lexaria Bioscience Corp. has a P/E of -2.0847 and an EV to EBITDA of -1.4100, while Cyclerion Therapeutics, Inc. has a P/E of -3.0156 and an EV to EBITDA of -1.8268, both indicating similar struggles within the industry. The company's stock has underperformed significantly against the S&P 500, with a year-to-date decline of 67.87% compared to the index's modest gain of 2.44%. Overall, the combination of these factors strongly suggests that Oragenics, Inc. is overvalued.

Q: Is Oragenics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Oragenics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI indicates bullish momentum weekly and monthly. However, moving averages are bearish on a daily basis, and the KST and Bollinger Bands are bearish on both weekly and monthly time frames. Dow Theory shows a mildly bullish stance weekly but bearish monthly, and OBV is mildly bullish weekly but bearish monthly.In terms of performance, Oragenics has significantly underperformed compared to the S&P 500, with a year-to-date return of -89.08% versus the S&P 500's 12.22%, and a one-year return of -91.65% compared to 17.14% for the index.

Results Declared: Oragenics, Inc. has declared results on 16 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

170.83 k

Shareholding (Dec 2025)

FII

0.85%

Held by 4 FIIs

DII

98.99%

Held by 0 DIIs

Promoter

0.00%

How big is Oragenics, Inc.?

22-Jun-2025

As of Jun 18, Oragenics, Inc. has a market capitalization of 3.13 million, with net sales of 0.00 million and a net profit of -10.34 million over the latest four quarters. The company reported shareholder's funds of -0.21 million and total assets of 1.47 million as of Dec 24.

View full answer

What does Oragenics, Inc. do?

22-Jun-2025

Oragenics, Inc. is a micro-cap healthcare company focused on developing treatments for oral mucositis and novel antibiotics. As of March 2025, it reported a net profit loss of $2 million and has a market cap of $3.13 million.

View full answer

Who are in the management team of Oragenics, Inc.?

22-Jun-2025

As of March 2022, the management team of Oragenics, Inc. includes Dr. Frederick Telling (Independent Chairman), Dr. Alan Joslyn (President and CEO), Ms. Kim Murphy, Dr. Alan Dunton, Mr. Robert Koski, and Mr. Charles Pope, all serving as directors. They are responsible for guiding the company's strategic direction and operations.

View full answer

Is Oragenics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 12, 2016, Oragenics, Inc. is considered overvalued due to its negative financial metrics, including a non-applicable P/E ratio, a Price to Book Value of 3.06, an EV to EBITDA of -0.22, and a severely low ROE of -1033.41%, alongside significant underperformance compared to the S&P 500.

View full answer

Is Oragenics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Oragenics, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with year-to-date returns of -89.08% compared to 12.22%.

View full answer

Compare Oragenics, Inc. with Similar Stocks

Lexaria Bioscience Corp.Sunshine Biopharma, Inc.Comera Life Sciences Holdings, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.12

Return on Equity

-110.92%

Price to Book

0.34

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.1%

6 Months

-49.67%

1 Year

-91.29%

2 Years

-98.46%

3 Years

-75.47%

4 Years

-99.9%

5 Years

-99.96%

Oragenics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

9.90%

EBIT to Interest (avg)

-15.52

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

2.81%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.34

EV to EBIT

0.75

EV to EBITDA

0.75

EV to Capital Employed

6.52

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

867.91%

ROE (Latest)

-110.92%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.16%)

Foreign Institutions

Held by 4 Foreign Institutions (0.85%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 25.81% vs -34.78% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.50",
          "val2": "-3.10",
          "chgp": "19.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.30",
          "val2": "-3.10",
          "chgp": "25.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 7.55% vs 48.79% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.40",
          "val2": "-10.60",
          "chgp": "11.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.80",
          "val2": "-10.60",
          "chgp": "7.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.50

-3.10

19.35%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.30

-3.10

25.81%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 25.81% vs -34.78% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.40

-10.60

11.32%

Interest

0.80

0.00

Exceptional Items

0.00

Consolidate Net Profit

-9.80

-10.60

7.55%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 7.55% vs 48.79% in Dec 2024

All Annual Results

Company CV

About Oragenics, Inc.

Oragenics, Inc.

Pharmaceuticals & Biotechnology

Oragenics, Inc. is a healthcare company. The Company is focused on developing treatments for oral mucositis and novel antibiotics against infectious disease. The Company is focused on developing of the TerraCoV2 immunization product candidate. The Company’s product candidate includes, OG716, as an antibiotic, as well as other homolog antibiotic product candidates and AG013 for the treatment of oral mucositis in patients undergoing treatment for cancer. The Company have developed other product such as weight loss candidate, LPT3-04 and SMaRT Replacement Therapy.

Company Coordinates

Company Details

4902 Eisenhower Blvd Ste 125 , TAMPA FL : 33634-6342

Tel: 1 813 2867900

https://www.oragenics.com/

Registrar Details